Methods of diagnosing and treating pre-eclampsia or eclampsia

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100, C435S007200, C514S002600, C514S012200, C530S350000

Reexamination Certificate

active

07435419

ABSTRACT:
Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia by detecting the levels of placental growth factor in a subject.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5238819 (1993-08-01), Roberts et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5543138 (1996-08-01), Keith
patent: 5712395 (1998-01-01), App et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5830879 (1998-11-01), Isner
patent: 5958715 (1999-09-01), Muller
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6258787 (2001-07-01), Isner
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 6399585 (2002-06-01), Larson et al.
patent: 6410322 (2002-06-01), Robinson
patent: 6447768 (2002-09-01), Van Zonneveld et al.
patent: 6660534 (2003-12-01), McVicker et al.
patent: 6677300 (2004-01-01), Schreiner et al.
patent: 2003/0114412 (2003-06-01), Ward et al.
patent: 2003/0144298 (2003-07-01), Curwen et al.
patent: 2003/0220262 (2003-11-01), Schreiner et al.
patent: 2004/0038305 (2004-02-01), Poston et al.
patent: 2004/0126828 (2004-07-01), Karumanchi et al.
patent: 2005/0025762 (2005-02-01), Karumanchi et al.
patent: 2005/0148023 (2005-07-01), Thadhani et al.
patent: 2005/0148040 (2005-07-01), Thadhani et al.
patent: 2006/0183175 (2006-08-01), Buhimschi et al.
patent: 1 417 971 (2004-05-01), None
patent: WO 98/28006 (1998-07-01), None
patent: WO 02/37120 (2002-05-01), None
patent: WO 2006/069373 (2006-06-01), None
Ferrara, N. Role of vascular endothelial growth factor in the regulation of angiogenesis, (1999) Kidney International, vol. 56, pp. 794-814.
Carmeliet et al., Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions, (2001) Nature Medicine, vol. 7, No. 5, pp. 575-583.
Torry et al., Expression and function of Placenta Growth Factor: Implications for abnormal placentation, 2003, Journal of Society Gynecology Investigation, vol 10, pp. 178-188.
Helske et al., “Expression of Vascular Endothelial Growth Factor Receptors 1, 2 and 3 in Placentas From Normal and Complicated Pregnancies,”Mol. Hum. Reprod. 7: 205-210 (2001).
Levine et al., “Urinary Placental Growth Factor and Risk of Preeclampsia,”JAMA293: 77-85 (2005).
Livingston et al., “Placenta Growth Factor is not an Early Marker for the Development of Severe Preeclampsia,”Am. J. Obstet. Gynecol. 184: 1218-1220 (2001).
Livingston et al., “Reductions of Vascular Endothelial Growth Factor and Placental Growth Factor Concentrations in Severe Preeclampsia,”Am. J. Obstet. Gynecol. 183: 1554-1557 (2000).
International Search Report Application No. PCT/US05/03884.
International Search Report Application No. PCT/US03/22892.
Foreign Search Report Application No. SG 200500265-4.
Ahmed et al., “Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Fit-1 by Oxygen—A Review,”Placenta21:S16-S24 (2000).
Baek et al., “Hypoxia-Induced VEGF Enhances Tumor Survivability Via Suppression of Serum Deprivation-Induced Apoptosis,”Oncogene19:4621-4631 (2000).
Barleon et al., “Soluble VEGFR-1 Secreted by Endothelial Cells and Monocytes is Present in Human Serum and Plasma from Healthy Donors,”Angiogenesis4:143-154 (2001).
Baumgartner et al., “Constitutive Expression of phVEGF165After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia,”Circulation97:1114-1123 (1998).
Belgore et al., “Measurement of Free and Complexed Soluble Vascular Endothelial Growth Factor Receptor, Fit-1, in Fluid Samples: Development and Application of Two New Immunoassays,”Clin. Sci. 100:567-575 (2001).
Belgore et al., “Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptor (SFit-1) in Essential Hypertension,”Am. J. Cardiol. 87:805-807 (2001).
Belgore et al., “sFit-1, a Potential Antagonist for Exogenous VEGF,”Circulation102:E108-E109 (2000).
Belgore et al., “Successful Therapy Reduces Levels of Vascular Endothelial Growth Factor (VEGF) in Patients with Hypertension and Patients with Hypercholesterolemia,”Atherosclerosis151:599 (2000).
Belgore et al., “Vascular Endothelial Growth Factor and its Receptor, Fit-1, in Smokers and Non-Smokers,”Br. J. Biomed. Sci. 57:207-213 (2000).
Blann et al., “Plasma Vascular Endothelial Growth Factor and Its Receptor Fit-1 in Patients with Hyperlipidemia and Atherosclerosis and the Effects of Fluvastatin or Fenofibrate,”Am. J. Cardiol. 87:1160-1163 (2001).
Brown et al., “Vascular Permeability Factor mRNA and Protein Expression in Human Kidney,”Kidney Int. 42:1457-1461 (1992).
Bouletreau et al., “Hypoxia and VEGF Up-Regulate BMP-2 mRNA and Protein Expression In Microvascular Endothelial Cells: Implications for Fracture Healing,”Plast. Reconstr. Surg. 109:2384-2397 (2002).
Celletti et al., “Effect of Human Recombinant Vascular Endothelial Growth Factor165 on Progression of Atherosclerotic Plaque,”J. Am. Coll. Cardiol. 37:2126-2130 (2001).
Charmock-Jones et al., Determination of the Circulating Levels of the Soluble Form of the VEGF-R1 (sFlt-1) in Women at High Risk of Developing Pre-Eclampsia,J. Soc. Gynecol. Investig. 10:166A Abstract No. 230 (2003).
Chamock-Jones et al., “Identification and Localization of Alternately Spliced mRNAs for Vascular Endothelial Growth Factor in Human Uterus and Estrogen Regulation in Endometrial Carcinoma Cell Lines,”Biol. Reprod. 48:1120-1128 (1993).
Clark et al., “A Vascular Endothelial Growth Factor Antagonist is Produced by the Human Placenta and Released into the Maternal Circulation,”Biol. Reprod. 59:1540-1548 (1998).
Cockell et al., “Human Placental Syncytiotrophoblast Microvillous Membranes Impair Maternal Vascular Endothelial Function,”Br. J. Obstet. Gynaecol. 104:235-240 (1997).
Cohen et al., “Amelioration of Diabetic Nephropathy by Treatment with Monoclonal Antibodies Against Glycated Albumin,”Kidney Int. 45:1673-1679 (1994).
Deodato et al., “Recombinant AAV Vector Encoding Human VEGF165 Enhances Wound Healing,”Gene Ther. 9:777-785 (2002).
Eddahibi et al., “Imbalance Between Platelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Pulmonary Hypertension,”Am. J. Respir. Crit. Care Med. 162:1493-1499 (2000).
Eremina et al., “Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases,”J. Clin. Invest. 111:707-716 (2003).
Ferguson, “Meeting Highlights: Highlights of the 48thScientific Sessions of the American College of Cardiology,”Circulation100:570-575 (1999).
Ferrara et al., “The Role of Vascular Endothelial Growth Factor in Angiogenesis,”Acta Haematol. 106:148-156 (2001).
Freedman et al., “Therapeutic Angiogenesis for Coronary Artery Disease,”Ann. Intern. Med. 136:54-71 (2002).
Gille et al., “Analysis of Biological Effects and Signaling Properties of Fit-1 (VEGFR-1) and KDR (VEGFR-2),”J. Biol. Chem, 276:3222-3230 (2001).
Graubert et al., “Vascular Repair After Menstruation Involves Regulation of Vascular Endothelial Growth Factor-Receptor Phosphorylation by sFLT-1,”Am. J. Pathol. 158:1399-1410 (2001).
Hayashi et al., “Changes in Urinary Excretion of Six Biochemical Parameters in Normotensive Pregnancy and Preeclampsia,”Am. J. Kidney Dis. 39:392-400 (2002).
He et al., “Alternative Splicing of Vascular Endothelial Growth Factor (VEGF)-R1 (FLT-1) Pre-mRNA is Important for the Regulation of VEGF Activity,”Mol. Endocrinol. 13:537-45 (1999).
He et al., “Vascular Endothelial Growth Factor Signals Endothelial Cell P

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of diagnosing and treating pre-eclampsia or eclampsia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of diagnosing and treating pre-eclampsia or eclampsia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing and treating pre-eclampsia or eclampsia will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4014993

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.